Mizuho raised the firm’s price target on Elevance Health (ELV) to $505 from $455 and keeps an Outperform rating on the shares. The firm ...

Barclays analyst Andrew Mok CFA maintained a Buy rating on Elevance Health (ELV – Research Report) today and set a price target of $512.00. The ...

Shares of Elevance Health, Inc. (NYSE:ELV – Get Free Report) have been given a consensus rating of “Moderate Buy” by the ...

Indianapolis-based health Elevance Health’s board is recommending its investors reject a shareholder proposal that asks the ...

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $477.08, along with a high estimate of $512.00 and a low estimate of $405.40. Marking an ...

Find out in our full research report, it’s free. Formerly known as Anthem until its 2022 rebranding, Elevance Health (NYSE:ELV) is one of America's largest health insurers, serving approximately ...

But ultimately the future profitability of the business will decide if Elevance Health can strengthen its balance sheet over time. So if you're focused on the future you can check out this free ...

Shares of Elevance Health Inc. ELV rallied 1.11% to $435.68 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 9.52% to ...

Elevance Health (NYSE:ELV – Get Free Report) last issued its quarterly earnings data on Thursday, January 23rd. The company reported $3.84 EPS for the quarter, topping analysts’ consensus ...

Hotchkis & Wiley, an investment management company, released its “Hotchkis & Wiley Large Cap Fundamental Value Fund” fourth ...

In its fourth quarter 2024 investor letter, Hotchkis & Wiley Large Cap Fundamental Value Fund emphasized stocks such as Elevance Health, Inc. (NYSE:ELV). Elevance Health, Inc. (NYSE:ELV) is a health ...